NICE minded to reject Keytruda for classical Hodgkin lymphoma
Cost regulators for NHS therapies in England and Wales say they are minded not to recommend funding for MSD’s Keytruda as a treatment for classical Hodgkin lymphoma, because its cost-effectiveness is uncertain.
Read More
